CMBA Notes - Lecture1...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Lecture 1 07/09/2010 11:14:00 Reading for Thursday: Sinha et al, Lancet, 2007. Cost Benefit: Always in dollar terms Cost Effectiveness: Not always, in our example it was “Life years gained” from a  vaccination Requisite sections of an analysis: - Objectives of the analysis: must mention a context, why does it make sense to  consider this policy. - Audience: Who does the report address? - Perspective: Which benefits count? Who or what will it affect? - Define program / policy being evaluated - Identify target population - Comparators - Time horizon - List benefits, costs and estimate benefits, costs. - Discount  - Computer cost-effectiveness ratio, net present value - Perform Sensitivity Analysis (Going over the reading from the packet almost no one has) CDC Recommends DTP at 2,4,6 and 15/18 months Booster before 6 years Then recommendation (since 1995) for booster after 12 years
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Tetanus boost recommended every 10 years after through adult hood A dose of tetnus vaccination in 1986 was less than a $1, and is currently only  ~$4. Markov Models In this case the health states are: o o o Have Tetanus o Die from Tetanus o Die from any other cause Must decide on a cycle length, this case is 1 year
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 6

CMBA Notes - Lecture1...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online